The Micoryx vaccine (clinicaltrials.gov, NCT01461148) encompasses antigens, which result from mutations of HT001 and AIM2. Consequently, frameshift peptide vaccination may represent a promising approach for tumour prevention in Lynch syndrome mutation carriers. Here, AIM2 is linked to Lynch syndrome.